[
  {
    "id": "PROC-OWS",
    "name": "Operation Warp Speed / Countermeasures Acceleration Group",
    "agency": "HHS and Department of Defense",
    "category": "Procurement and executive delivery",
    "authority": "Executive interagency initiative using COVID supplemental appropriations",
    "funding_usd": 16300000000.0,
    "funding_basis": "At least this amount obligated; early-program snapshot",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "Through 2020-12-31",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-21-265/index.html"
    ],
    "notes": "Includes development, manufacture and distribution of vaccines and therapeutics; later renamed CAG and transitioned to HHS. This early benchmark does not represent final lifetime procurement. Source reports two announced awards without identifiable procurement obligations. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-OWS-VACCINES",
    "name": "Operation Warp Speed vaccine development and dose procurement",
    "agency": "HHS and Department of Defense",
    "category": "Procurement and executive delivery",
    "authority": "Executive interagency initiative; COVID supplemental funds",
    "funding_usd": 13000000000.0,
    "funding_basis": "Approximate obligations to six pharmaceutical companies",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "Through 2020-12-31",
    "parent_id": "PROC-OWS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-21-265/index.html"
    ],
    "notes": "Vaccine component within the OWS parent; subsequent purchases extend beyond this early snapshot. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-OWS-THERAPEUTICS",
    "name": "Operation Warp Speed therapeutics",
    "agency": "HHS and Department of Defense",
    "category": "Procurement and executive delivery",
    "authority": "Executive interagency initiative; COVID supplemental funds",
    "funding_usd": 2000000000.0,
    "funding_basis": "Approximately this amount obligated",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "Through 2020-12-31",
    "parent_id": "PROC-OWS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-21-265/index.html"
    ],
    "notes": "Source says almost $2 billion; therapeutic component nested within the OWS parent. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-DPA-CARES",
    "name": "Defense Production Act COVID purchases: CARES tranche",
    "agency": "Department of Defense",
    "category": "Procurement and executive delivery",
    "authority": "CARES Act; Defense Production Act authorities",
    "funding_usd": 1000000000.0,
    "funding_basis": "Original appropriation",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2020",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.gao.gov/products/gao-22-105380"
    ],
    "notes": "GAO identifies at least $11 billion across this tranche and ARPA medical supply funding; program also used priority ratings with no separate spending amount. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-DPA-ARPA",
    "name": "Defense Production Act medical supply investments: ARPA tranche",
    "agency": "HHS",
    "category": "Procurement and executive delivery",
    "authority": "ARPA section 3101; Defense Production Act authorities",
    "funding_usd": 10000000000.0,
    "funding_basis": "Original appropriation",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2021; funding available through September 2025",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.gao.gov/products/gao-22-105380"
    ],
    "notes": "Medical supply purchases, production and distribution; includes future public-health emergency preparedness as authorized. Later rescissions and transfers affect net resources. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-SNS",
    "name": "Strategic National Stockpile COVID supplies",
    "agency": "HHS / ASPR",
    "category": "Procurement and executive delivery",
    "authority": "COVID supplemental appropriations and HHS procurement authority",
    "funding_usd": 6100000000.0,
    "funding_basis": "Obligations for critical COVID supplies delivered directly to the stockpile",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "FY2020–FY2021",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.gao.gov/assets/d24106260.pdf"
    ],
    "notes": "Includes $2.4 billion for PPE. Source also records $1.4 billion for direct shipment to jurisdictions; these delivery scopes remain separate. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-SNS-DIRECT",
    "name": "ASPR COVID supplies delivered directly to jurisdictions",
    "agency": "HHS / ASPR",
    "category": "Procurement and executive delivery",
    "authority": "COVID supplemental appropriations and HHS procurement authority",
    "funding_usd": 1400000000.0,
    "funding_basis": "Obligations for direct shipments, including PPE",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "FY2020–FY2021",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.gao.gov/assets/d24106260.pdf"
    ],
    "notes": "Delivery to jurisdictions is a separate source category from critical supplies delivered directly to the stockpile. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-RADX",
    "name": "Rapid Acceleration of Diagnostics (RADx)",
    "agency": "HHS / NIH",
    "category": "Procurement and executive delivery",
    "authority": "Paycheck Protection Program and Health Care Enhancement Act",
    "funding_usd": 1500000000.0,
    "funding_basis": "Initial supplemental funding",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "April 2020 launch",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.nih.gov/news-events/news-releases/nih-leadership-details-unprecedented-initiative-ramp-testing-technologies-covid-19"
    ],
    "notes": "NIH diagnostic testing initiative; nested grant and contract awards also appear in NIH accounts and assistance listings. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-RADX-TECH",
    "name": "RADx Tech",
    "agency": "HHS / NIH",
    "category": "Procurement and executive delivery",
    "authority": "NIH RADx initiative",
    "funding_usd": null,
    "funding_basis": "Component of RADx; separate final spending not assigned",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2020 onward",
    "parent_id": "PROC-RADX",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.nih.gov/news-events/news-releases/nih-leadership-details-unprecedented-initiative-ramp-testing-technologies-covid-19"
    ],
    "notes": "Named implementation component; parent funding retained without apportioning it. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-RADX-ATP",
    "name": "RADx Advanced Technology Platforms",
    "agency": "HHS / NIH",
    "category": "Procurement and executive delivery",
    "authority": "NIH RADx initiative",
    "funding_usd": null,
    "funding_basis": "Component of RADx; separate final spending not assigned",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2020 onward",
    "parent_id": "PROC-RADX",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.nih.gov/news-events/news-releases/nih-leadership-details-unprecedented-initiative-ramp-testing-technologies-covid-19"
    ],
    "notes": "Named implementation component; parent funding retained without apportioning it. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-RADX-UP",
    "name": "RADx Underserved Populations",
    "agency": "HHS / NIH",
    "category": "Procurement and executive delivery",
    "authority": "NIH RADx initiative",
    "funding_usd": null,
    "funding_basis": "Component of RADx; separate final spending not assigned",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2020 onward",
    "parent_id": "PROC-RADX",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.nih.gov/news-events/news-releases/nih-leadership-details-unprecedented-initiative-ramp-testing-technologies-covid-19"
    ],
    "notes": "Named implementation component; parent funding retained without apportioning it. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-RADX-RAD",
    "name": "RADx Radical",
    "agency": "HHS / NIH",
    "category": "Procurement and executive delivery",
    "authority": "NIH RADx initiative",
    "funding_usd": null,
    "funding_basis": "Component of RADx; separate final spending not assigned",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2020 onward",
    "parent_id": "PROC-RADX",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.nih.gov/news-events/news-releases/nih-leadership-details-unprecedented-initiative-ramp-testing-technologies-covid-19"
    ],
    "notes": "Named implementation component; parent funding retained without apportioning it. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-RECOVER",
    "name": "Researching COVID to Enhance Recovery (RECOVER)",
    "agency": "HHS / NIH",
    "category": "Procurement and executive delivery",
    "authority": "P.L. 116-260 and subsequent reallocation of HHS supplemental balances",
    "funding_usd": 1812000000.0,
    "funding_basis": "Initial $1.15 billion plus $662 million subsequent funding",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2020 appropriation and 2024 additional funding; planned use through FY2029",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://recovercovid.org/funding"
    ],
    "notes": "Computed sum of two published funding tranches. The $662 million includes $515 million and a December 2024 $147 million reallocation; future allocations remain distinct from expenditures. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-NEXTGEN",
    "name": "Project NextGen vaccine and therapeutic development",
    "agency": "HHS / BARDA and NIAID",
    "category": "Procurement and executive delivery",
    "authority": "Executive allocation of HHS COVID response funds",
    "funding_usd": 5000000000.0,
    "funding_basis": "Announced initial investment",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2023 initiative",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.hhs.gov/sites/default/files/fy-2023-hhs-agency-financial-report.pdf"
    ],
    "notes": "Original investment benchmark; subsequent award terminations, reallocations and policy changes mean this is not a current net spending measure. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-BRIDGE",
    "name": "Bridge Access Program for COVID vaccines and treatments",
    "agency": "HHS / CDC and HRSA",
    "category": "Procurement and executive delivery",
    "authority": "HHS executive program allocation",
    "funding_usd": 1100000000.0,
    "funding_basis": "Announced public-private partnership funding",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2023–2024",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.hhs.gov/sites/default/files/bhm-fact-sheet-020124_0.pdf"
    ],
    "notes": "Provided continued access for uninsured and underinsured people as vaccine commercialization proceeded; the source is a February 2024 funding statement. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-TESTS",
    "name": "Federal over-the-counter COVID test procurement",
    "agency": "HHS / ASPR and Department of Defense",
    "category": "Procurement and executive delivery",
    "authority": "HHS and Defense procurement using pandemic response funds",
    "funding_usd": 9325000000.0,
    "funding_basis": "Approximate cost of tests contracted and purchased",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "FY2021–FY2023; February 2023 congressional response",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.congress.gov/118/meeting/house/115351/witnesses/HHRG-118-IF02-Wstate-OConnellwasinvitedbutcouldnotattendT-20230208-SD002.pdf"
    ],
    "notes": "Congressional response pages 3–6 covers tests supporting both USPS household delivery and the Testing and Diagnostics Working Group distribution channels; avoid assigning the entire amount to either channel. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-TESTS-USPS",
    "name": "COVIDTests.gov / At Home Delivery Program",
    "agency": "HHS / ASPR and USPS",
    "category": "Procurement and executive delivery",
    "authority": "Executive at-home testing initiative",
    "funding_usd": null,
    "funding_basis": "Distribution channel within federal test procurement; separate combined procurement/delivery amount unassigned",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "January 2022 onward",
    "parent_id": "PROC-TESTS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.congress.gov/118/meeting/house/115351/witnesses/HHRG-118-IF02-Wstate-OConnellwasinvitedbutcouldnotattendT-20230208-SD002.pdf"
    ],
    "notes": "The source reports 753 million tests mailed by February 2023 and separates test purchasing from shipping. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-TESTS-TDWG",
    "name": "Testing and Diagnostics Working Group test distribution",
    "agency": "HHS / ASPR",
    "category": "Procurement and executive delivery",
    "authority": "HHS pandemic distribution authority",
    "funding_usd": 37100000.0,
    "funding_basis": "Shipping cost only",
    "outlay_usd": 37100000.0,
    "loan_principal_usd": null,
    "period": "Through February 2023",
    "parent_id": "PROC-TESTS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.congress.gov/118/meeting/house/115351/witnesses/HHRG-118-IF02-Wstate-OConnellwasinvitedbutcouldnotattendT-20230208-SD002.pdf"
    ],
    "notes": "Source reports over 417 million tests distributed through this channel. The amount is shipping expenditure, excluding test acquisition. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-AIRBRIDGE",
    "name": "Project Airbridge emergency PPE transport",
    "agency": "FEMA",
    "category": "Procurement and executive delivery",
    "authority": "Stafford Act emergency response and FEMA executive initiative",
    "funding_usd": 238000000.0,
    "funding_basis": "Approximate program expenditures",
    "outlay_usd": 238000000.0,
    "loan_principal_usd": null,
    "period": "March–June 2020; audit issued February 2023",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.oig.dhs.gov/sites/default/files/assets/2023-02/OIG-23-14-Feb23.pdf"
    ],
    "notes": "DHS OIG found insufficient oversight and failure to verify supply-chain needs; that performance finding supplies no measured fraud total. Overlaps federal agency and account spending.",
    "fraud_keys": [
      "project_airbridge"
    ],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "PROC-FOODBOX",
    "name": "Farmers to Families Food Box Program",
    "agency": "USDA / Agricultural Marketing Service",
    "category": "Procurement and executive delivery",
    "authority": "Families First Coronavirus Response Act procurement flexibility",
    "funding_usd": 5500000000.0,
    "funding_basis": "Approximate total program cost",
    "outlay_usd": 5500000000.0,
    "loan_principal_usd": null,
    "period": "May 2020–May 2021",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://ers.usda.gov/data-products/charts-of-note/104314"
    ],
    "notes": "USDA ERS reports 176.4 million boxes; program procurement overlaps USDA accounts and the broader Coronavirus Food Assistance Program label. Overlaps federal agency and account spending.",
    "fraud_keys": [
      "food_box"
    ],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "DETAIL-USPS-OPERATING",
    "name": "USPS CARES pandemic operating-expense assistance",
    "agency": "USPS / Treasury",
    "category": "Program detail",
    "authority": "CARES Act as amended by P.L. 116-260",
    "funding_usd": 10000000000.0,
    "funding_basis": "Authorized funding request ceiling",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "January 2021 Treasury agreement",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://www.uspsoig.gov/reports/audit-reports/coronavirus-aid-relief-and-economic-security-cares-act-funding"
    ],
    "notes": "Postal Service OIG reviewed accounting, allowable expenses and internal controls. Original CARES borrowing authority later became reimbursement support; the cap is separate from actual outlays. Overlaps federal agency and account spending.",
    "fraud_keys": [
      "usps_relief"
    ],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "DETAIL-PEAF",
    "name": "Pandemic Emergency Assistance Fund (PEAF)",
    "agency": "HHS / ACF",
    "category": "Program detail",
    "authority": "ARPA section 9201",
    "funding_usd": 1000000000.0,
    "funding_basis": "Original appropriation",
    "outlay_usd": null,
    "loan_principal_usd": null,
    "period": "2021 allocations; initial liquidation by September 2022",
    "parent_id": "ALN-93.558",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://acf.gov/archive/grant-funding/arp-funding-matrix"
    ],
    "notes": "Nonrecurrent short-term benefits for low-income families through states, territories and tribal TANF programs; nested under TANF accounts and ALN93.558. Overlaps federal agency and account spending.",
    "fraud_keys": [
      "peaf"
    ],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "DETAIL-AVIATION-LOANS",
    "name": "Aviation and National Security Business Loan Program",
    "agency": "Treasury",
    "category": "Program detail",
    "authority": "CARES Act section 4003(b)(1)–(3)",
    "funding_usd": 2677984000,
    "funding_basis": "Gross loan principal disbursed; GAO table in thousands converted to dollars",
    "outlay_usd": null,
    "loan_principal_usd": 2677984000,
    "period": "Status as of April 2026",
    "parent_id": null,
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-26-108011/index.html"
    ],
    "notes": "35 executed loans authorized $21.890984 billion within a $46 billion statutory ceiling. Principal repayments $2.683235 billion include payment-in-kind interest; cash interest receipts $204.246 million. Outstanding balance $61.684 million. Repayment/default figures do not measure fraud. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "DETAIL-AVIATION-LOANS-CARGO-AIR-CARRIERS",
    "name": "Cargo air carriers: CARES section 4003 loans",
    "agency": "Treasury",
    "category": "Program detail",
    "authority": "CARES Act section 4003(b)(1)–(3)",
    "funding_usd": 2112000,
    "funding_basis": "Gross loan principal disbursed",
    "outlay_usd": null,
    "loan_principal_usd": 2112000,
    "period": "Status as of April 2026",
    "parent_id": "DETAIL-AVIATION-LOANS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-26-108011/index.html"
    ],
    "notes": "Executed loan authority $2,112,000. Child of the aviation and national security business loan program. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "DETAIL-AVIATION-LOANS-PASSENGER-AIR-CARRIERS",
    "name": "Passenger air carriers: CARES section 4003 loans",
    "agency": "Treasury",
    "category": "Program detail",
    "authority": "CARES Act section 4003(b)(1)–(3)",
    "funding_usd": 1900400000,
    "funding_basis": "Gross loan principal disbursed",
    "outlay_usd": null,
    "loan_principal_usd": 1900400000,
    "period": "Status as of April 2026",
    "parent_id": "DETAIL-AVIATION-LOANS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-26-108011/index.html"
    ],
    "notes": "Executed loan authority $21,113,400,000. Child of the aviation and national security business loan program. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "DETAIL-AVIATION-LOANS-REPAIR-STATION-OPERATORS",
    "name": "Repair station operators: CARES section 4003 loans",
    "agency": "Treasury",
    "category": "Program detail",
    "authority": "CARES Act section 4003(b)(1)–(3)",
    "funding_usd": 18988000,
    "funding_basis": "Gross loan principal disbursed",
    "outlay_usd": null,
    "loan_principal_usd": 18988000,
    "period": "Status as of April 2026",
    "parent_id": "DETAIL-AVIATION-LOANS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-26-108011/index.html"
    ],
    "notes": "Executed loan authority $18,988,000. Child of the aviation and national security business loan program. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "DETAIL-AVIATION-LOANS-TICKET-AGENTS",
    "name": "Ticket agents: CARES section 4003 loans",
    "agency": "Treasury",
    "category": "Program detail",
    "authority": "CARES Act section 4003(b)(1)–(3)",
    "funding_usd": 20550000,
    "funding_basis": "Gross loan principal disbursed",
    "outlay_usd": null,
    "loan_principal_usd": 20550000,
    "period": "Status as of April 2026",
    "parent_id": "DETAIL-AVIATION-LOANS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-26-108011/index.html"
    ],
    "notes": "Executed loan authority $20,550,000. Child of the aviation and national security business loan program. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  },
  {
    "id": "DETAIL-AVIATION-LOANS-NATIONAL-SECURITY-BUSINESSES",
    "name": "National security businesses: CARES section 4003 loans",
    "agency": "Treasury",
    "category": "Program detail",
    "authority": "CARES Act section 4003(b)(1)–(3)",
    "funding_usd": 735934000,
    "funding_basis": "Gross loan principal disbursed",
    "outlay_usd": null,
    "loan_principal_usd": 735934000,
    "period": "Status as of April 2026",
    "parent_id": "DETAIL-AVIATION-LOANS",
    "additive_group": "overlapping_program_benchmarks",
    "source_urls": [
      "https://files.gao.gov/reports/GAO-26-108011/index.html"
    ],
    "notes": "Executed loan authority $735,934,000. Child of the aviation and national security business loan program. Overlaps federal agency and account spending.",
    "fraud_keys": [],
    "fraud_assessment": "Program-wide fraud unquantified in reviewed evidence"
  }
]